These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32311891)

  • 1. [Clinical characteristics of 83 patients with thrombotic thrombocytopenic purpura].
    Wang XY; Liu XF; Xue F; Liu W; Chen YF; Huang YT; Fu RF; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):216-221. PubMed ID: 32311891
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical characteristics and outcome of 69 patients with thrombotic thrombocytopenic purpura].
    Zhang JL; Xing HZ; Wang F; Wan DM; Jiang ZX; Wang M
    Zhonghua Nei Ke Za Zhi; 2022 Jul; 61(7):797-800. PubMed ID: 35764564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of 61 patients with thrombotic thrombocytopenic purpura].
    Shi MJ; Gao WB; Huang WF; Zhu JH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Sep; 53(1):210-214. PubMed ID: 33550359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of thrombotic thrombocytopenic purpura in two French centers: A series of 27 patients].
    Deroux A; Sirodot M; Daguindau N; Barro C; Coppo P; Bouillet L
    Rev Med Interne; 2016 Jan; 37(1):13-8. PubMed ID: 26065327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of 14 patients with thrombotic thrombocytopenic purpura].
    Wang Y; Zhang JY; Niu ZY; Lin FR; Zhou JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):407-11. PubMed ID: 24763014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
    Liu F; Lu GY; Dong NZ; Bai X; Su J; Ruan CG
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3190-3. PubMed ID: 16405838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.
    Vazquez-Mellado A; Pequeño-Luévano M; Cantu-Rodriguez OG; Villarreal-Martínez L; Jaime-Pérez JC; Gomez-De-Leon A; De La Garza-Salazar F; Gonzalez-Llano O; Colunga-Pedraza P; Sotomayor-Duque G; Gomez-Almaguer D
    Hematology; 2016 Jun; 21(5):311-6. PubMed ID: 26907228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
    Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
    Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
    Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
    Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
    Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.
    Som S; Deford CC; Kaiser ML; Terrell DR; Kremer Hovinga JA; Lämmle B; George JN; Vesely SK
    Transfusion; 2012 Dec; 52(12):2525-32; quiz 2524. PubMed ID: 22501034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
    Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
    Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
    Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.
    Galbusera M; Bresin E; Noris M; Gastoldi S; Belotti D; Capoferri C; Daina E; Perseghin P; Scheiflinger F; Fakhouri F; Grünfeld JP; Pogliani E; Remuzzi G
    Blood; 2005 Aug; 106(3):925-8. PubMed ID: 15827129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.